Pre-Open Stock Movers 10/08: (JMG) (BMR) (EMC) Higher; (CSII) (ORIG) (SHAK) Lower (more...)

October 8, 2015 9:28 AM EDT

Journal Media Group, Inc. (NYSE: JMG) 42% HIGHER; Gannett (NYSE: GCI) and Journal Media Group, Inc. (NYSE: JMG) announced that they have entered into a definitive merger agreement under which Gannett will acquire all of the outstanding common stock of Journal Media Group for approximately $280 million, net of acquired cash.

Cardiovascular Systems (NASDAQ: CSII) 25.9% LOWER; reported preliminary results for its fiscal 2016 first quarter ended September 30, 2015. The company expects fiscal first-quarter revenues of approximately $43.9 million, an 11 percent increase from $39.5 million in the first quarter of fiscal 2015, excluding $1.9 million from the sale of Asahi guide wires in the prior year period. The fiscal 2016 first quarter net loss is anticipated to be in the range of $(13.1) million to $(13.9) million, or $(0.41) to $(0.43) per common share, compared to a net loss of $(8.2) million, or $(0.26) per common share, in the fiscal 2015 first quarter. CSIs fiscal 2016 first-quarter results are preliminary and may change as the company completes its customary close procedures and independent auditor review. *** The Street sees Q2 revenue of $49.4 and loss of $0.39 per share.

Neurocrine Biosciences (NASDAQ: NBIX) 16.3% HIGHER; announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

Ocean Rig UDW Inc. (NASDAQ: ORIG) 16% LOWER; The Ocean Rig Mylos is in the process of completing its current well in Brazil. On September 25, 2015 we received notice of material breach under the contract which entitles our client to terminate the contract if such breach is not remedied within 75 days. We believe that such notice is totally without merit and we intend to vigorously defend our rights under the contract.

Nivalis Therapeutics (NASDAQ: NVLS) 13% HIGHER; announced positive topline results from a Phase 1b clinical study evaluating N91115 that demonstrated favorable safety, tolerability and pharmacokinetics in adult CF patients with two copies of the F508del-CFTR mutation. N91115 is the Company’s novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Lumber Liquidators (NYSE: LL) 11.5% HIGHER; announced a settlement with the Environment and Natural Resources Division of the Department of Justice related to the Company's compliance with the Lacey Act, a U.S. conservation law regarding the protection of plants, fish and wildlife. This concludes the DOJ's inquiry launched in 2013, which primarily related to certain foreign suppliers harvesting more timber than their permits allowed in foreign jurisdictions, such as Eastern Russia, and the Company's importation of flooring products made from this timber. This matter focused on some of the Company's hardwood flooring purchase orders and import declarations made concerning the origin of the timber of those orders.

Novocure (NASDAQ: NVCR) 11% HIGHER; positive comments from CNBC's Mad Money host Jim Cramer.

Biomed Realty Trust (NYSE: BMR) 8.6% HIGHER; announced that it has entered into a definitive agreement with affiliates of Blackstone Real Estate Partners VIII, under which Blackstone will acquire all outstanding shares of common stock of BioMed Realty for $23.75 per share in an all-cash transaction valued at $8 billion.

Chemours Co. (NYSE: CC) 7.8% HIGHER; Apollo Global Management (NYSE: APO) is said to be mulling a takeover of Chemours Co. (NYSE: CC), which was a former unit of DuPont.

Shake Shack (NYSE: SHAK) 7.3% LOWER; filed a registration with the U.S. SEC to sell up to 26,160,694 shares of its common stock on behalf of selling shareholders.

Qualys (NASDAQ: QLYS) 7% HIGHER; Credit Suisse upgraded from Neutral to Outperform with a price target of $45.00 (from $35.00).

Lion Biotechnologies (NASDAQ: LBIO) 5.6% HIGHER; Chardan Capital Markets analyst Gbola Amusa reiterated a Buy rating and boosted the price target to $20.00

Deutsche Bank AG (NYSE: DB) 5% LOWER; reports large write-down, may suspend dividend.

Mistras Group, Inc. (NYSE: MG) 5% HIGHER; reported Q1 EPS of $0.23, $0.14 better than the analyst estimate of $0.09. Revenue for the quarter came in at $179.9 million versus the consensus estimate of $163.47 million. Mistras Group, Inc. sees FY2015 revenue of $710-725 million, versus the consensus of $716.87 million. The Company also announced that its Board of Directors authorized a stock repurchase program of up to $50 million of the Company's outstanding common stock.

Domino's Pizza (NYSE: DPZ) 4.7% LOWER; reported Q3 EPS of $0.67, $0.07 worse than the analyst estimate of $0.74. Revenue for the quarter came in at $494.7 million versus the consensus estimate of $486 million.

EMC Corp. (NYSE: EMC) 4.5% HIGHER; PC-maker Dell is in talks to merge with EMC Corp. (NYSE: EMC), the Wall Street Journal reported late Wednesday.

Metabolix, Inc. (NASDAQ: MBLX) 3.3% HIGHER; entered into a $20 million common stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, Aspire has committed to purchase up to $20 million of Metabolix’s common stock over a 30 month period beginning on the effective date of the registration statement relating to the transaction. Common stock may be sold from time to time at the company’s option under a pricing formula based on prevailing market prices around the time of each sale.

Groupon, Inc. (NASDAQ: GRPN) 3% LOWER; Cowen initiates coverage with a Underperform rating and a price target of $2.75.

Navient Corporation (NASDAQ: NAVI) 3% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $15.00.

EXFO, Inc. (NASDAQ: EXFO) 1% LOWER; reported Q4 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $56.6 million versus the consensus estimate of $58.18 million. EXFO, Inc. sees FY2016 revenue of $230 million, versus the consensus of $233.08 million.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Jim Cramer, Credit Suisse, Deutsche Bank, Goldman Sachs, Cowen & Co, Pre-Open Losers, Pre-Open Winners, Chardan Capital Markets, Definitive Agreement, Pre Market Movers